Short answer: how to value a medical practice

Value a medical practice by (1) normalizing EBITDA to remove owner-physician compensation above fair market value, non-recurring costs, and personal expenses, (2) applying a specialty-specific EBITDA multiple that reflects current MSO and private equity buyer appetite, and (3) valuing the professional corporation and the MSO separately when a corporate-practice-of-medicine state requires the split. Typical 2026 EBITDA multiples run 4x to 15x depending on specialty, scale, payer mix, and buyer type.

The valuation framework in one page

Medical practice valuation follows the same three approaches used across mid-market M&A: income, market, and asset. The income approach discounts projected cash flow. The market approach applies transaction multiples from comparable deals. The asset approach sums tangible and intangible assets. For an operating practice with recurring patient revenue, buyers weight the income and market approaches; the asset approach is a floor, not a driver.

Step-by-step method

1. Pull three years of financials. Trailing twelve months (TTM) plus two prior years, on a cash-to-accrual reconciled basis.
2. Normalize EBITDA. Add back owner-physician compensation above fair market value (FMV) as defined by HHS OIG, non-recurring legal or IT costs, personal auto and travel, and related-party rent above market.
3. Benchmark FMV compensation. Use MGMA Provider Compensation, SullivanCotter, or ECG Physician Compensation surveys.
4. Select a multiple. Anchor to specialty-specific transaction comps (see the table below).
5. Value real estate separately. Practice-owned real estate is a distinct asset priced on a cap rate, not the EBITDA multiple.
6. Split PC vs MSO. In corporate-practice-of-medicine (CPOM) states, the physician-owned PC and the MSO are valued separately and papered as two entities.
7. Sensitivity-test. Run high, base, and low multiple scenarios, and run an income-approach cross-check using a discount rate anchored to Damodaran healthcare cost of capital data.

How to normalize EBITDA for a medical practice

Normalized EBITDA is the single biggest number in the valuation. Buyers pay a multiple of normalized EBITDA, not reported EBITDA, so every dollar of defensible adjustment is worth the multiple in enterprise value. In a specialty trading at 10x, one dollar of add-back equals ten dollars of price. The bar for defensibility is set in diligence by the buyer’s Quality of Earnings (QoE) firm.

Common add-backs buyers accept

• Owner-physician compensation above MGMA or SullivanCotter FMV for the specialty and region.
• Non-recurring legal, IT migration, or one-time equipment purchases.
• Related-party rent above market (documented with a broker opinion).
• Personal expenses run through the practice: auto, travel, phones, meals.
• COVID-era Provider Relief Fund distortions, per HRSA guidance.
• Discontinued service lines or closed locations.

Common add-backs buyers reject

• Owner compensation reduced below FMV (this is a below-market clawback, not an add-back).
• Projected synergies from the buyer’s operation.
• Marketing spend cuts that would reduce future patient volume.
• Compensation add-backs unsupported by an FMV benchmark.

For a deeper walkthrough of what QoE firms accept and reject, see Quality of Earnings Report: Seller Deep Dive.

Medical practice EBITDA multiples by specialty (2026 benchmarks)

The table below reflects CT Acquisitions’ compiled 2025-2026 lower-middle-market transaction benchmarks, cross-referenced with public disclosures from VMG Health, Provident Healthcare Partners, PYA, and Bain Global Healthcare Private Equity Report. Ranges assume normalized EBITDA above $1M and a scaled buyer (platform, add-on to a platform, or strategic MSO). Micro-practices with sub-$500K EBITDA generally trade below the low end.

Notes on the ranges. Multiples are on post-MSO EBITDA, meaning EBITDA after paying the physician-owners a market clinical wage. Pre-MSO EBITDA multiples are meaningfully higher and are not comparable. Deals at or above $10M EBITDA typically clear the top of the range; sub-$1M EBITDA typically trades below the low end.

Valuation by specialty: routing to deeper benchmarks

The multiple range in the table above is the entry point. Every specialty has its own deal structure, EBITDA definition, and buyer roster. For the actual number you should walk into your process with, use CT’s sub-vertical valuation guides:

• Physical Therapy M&A Multiples 2026 covers PT platform economics, visit yield, and payer-mix impact on multiples.
• Optometry M&A Multiples 2026 covers optical retail contribution, private-pay mix, and OD/MD hybrid platforms.
• Med Spa M&A Multiples 2026 covers membership economics, injector cost, and CPOM-driven structure.
• Veterinary Practice M&A Multiples 2026 covers the highest-multiple specialty, associate use, and post-COVID normalization.
• Dermatology M&A Multiples 2026 covers Mohs, path lab ancillaries, and cosmetic mix impact.

Each sub-page carries the granular buyer list, recent transaction comps, and the specialty-specific EBITDA definition your buyers will use.

PC and MSO: why medical practice valuation splits in two

Medical practice valuation splits into two entities in states enforcing the corporate practice of medicine (CPOM) doctrine. The physician-owned professional corporation (PC) holds the clinical license and bills payers. The management services organization (MSO) holds everything else: real estate leases, equipment, staff (non-clinical), IT, billing, and management. A private-equity buyer purchases the MSO and enters a long-term management services agreement with the PC. The multiple is applied to MSO EBITDA, not PC EBITDA.

Which states enforce CPOM?

CPOM enforcement varies widely. California, New York, Texas, New Jersey, Illinois, Ohio, Colorado, and Iowa are historically strict CPOM states; Florida, Arizona, and most southeastern states are permissive. The FTC, HHS, and DOJ joint inquiry launched in June 2024 and state legislation in California (AB 3129, vetoed 2024), Oregon (SB 951, signed 2025), and Washington (HB 2548) has tightened CPOM enforcement and MSO structural review.

Structural implications for the multiple

Because the PC’s clinical revenue flows to the MSO through a management fee, buyers underwrite the sustainability of that fee. Regulators, notably HHS OIG and state medical boards, may re-characterize an excessive management fee as fee-splitting or a violation of the Anti-Kickback Statute (AKS). That risk shows up in the multiple as a discount for CPOM states, typically 0.5x to 1.5x lower than the same practice in a permissive state.

Personal goodwill vs enterprise goodwill

Personal goodwill is the intangible value tied to the individual physician (name, referrals, patient loyalty). Enterprise goodwill is tied to the business itself (brand, systems, location, contracts). The split matters because personal goodwill sold by an owner-physician is taxed at long-term capital gains rates, while enterprise goodwill sold inside a C-corp faces double taxation.

The seminal case is Martin Ice Cream Co. v. Commissioner, 110 T.C. 189 (1998), extended in healthcare by H&M Inc. v. Commissioner, T.C. Memo 2012-290. Allocating value to personal goodwill can save 10 to 20 points of effective tax rate on the personal-goodwill slice; buyers routinely resist because it reduces their tax basis and their non-compete use.

Non-compete and restrictive covenants: post-Ryan v. FTC

The FTC’s April 2024 non-compete rule was vacated nationwide by the Northern District of Texas in Ryan LLC v. FTC on August 20, 2024, and the ruling was affirmed on the Fifth Circuit docket in 2025. As of July 2026, physician non-competes are governed by state law, and state law varies widely. California, Minnesota, North Dakota, and Oklahoma broadly prohibit them. Colorado, Illinois, and Washington limit them by salary threshold. Most other states enforce reasonable time and geography restrictions.

For a valuation, the non-compete matters two ways: (1) buyers apply a discount if the seller cannot deliver enforceable non-competes on the retained physicians, and (2) allocation of purchase price to a non-compete generates Class VI intangible under IRC 197, amortizable over 15 years by the buyer and ordinary income to the seller.

How to handle practice-owned real estate

Practice-owned real estate is valued separately from the operating business. Buyers price real estate on a capitalization rate, not an EBITDA multiple, and typically prefer to leaseback the property rather than buy it. A market-rate triple-net lease of 12 to 18 years is standard. The rent used in the practice’s normalized EBITDA must equal the leaseback rent, not the below-market related-party rent the owner may have been paying.

Medical office building (MOB) cap rates in 2025 ran 6.5 percent to 7.5 percent for on-campus properties and 7.0 percent to 8.5 percent for off-campus, per CBRE US MOB reports and Marcus & Millichap data. If the practice owner will retain the real estate, the leaseback creates a separate long-duration income stream at those cap rates.

Regulatory fair-market-value guardrails: Stark, AKS, and CMP

Federal healthcare fraud statutes constrain what any buyer can pay. The Stark Law (Section 1877 of the Social Security Act), the Anti-Kickback Statute, and the Civil Monetary Penalties Law all require that transactions with referring physicians be at commercially reasonable fair market value. In a physician practice acquisition, this shapes:

• Purchase price allocation. Value assigned to referring physicians must be independently FMV-supported.
• Retention compensation. Post-close physician wages must be at MGMA-benchmarked FMV, not inflated to reward past referrals.
• Earnouts. Earnouts tied to referrals or federal-program volume are prohibited. Earnouts tied to same-store growth or synergies are permitted.

A written FMV opinion from a qualified valuation firm is table stakes when a hospital, health system, or health-plan buyer is involved, per HHS OIG Advisory Opinion 21-02 and related guidance.

Who buys medical practices in 2026?

The 2026 buyer pool falls into five distinct pockets, each with its own valuation lens.

1. PE-backed MSO platforms

The dominant buyer of $2M+ EBITDA practices in dermatology, ophthalmology, GI, cardiology, and orthopedics. Platforms typically pay 8x to 14x post-MSO EBITDA and structure rollover equity of 20 to 40 percent. Bain’s 2025 Healthcare Private Equity Report tracks over 150 active healthcare services platforms.

2. Hospital and health system buyers

Hospital acquisitions of physician practices remain material despite regulatory scrutiny. Health systems typically pay lower headline multiples (5x to 8x) but include integration compensation and referral-corridor benefits, all subject to Stark/AKS FMV constraints.

3. Payer-owned platforms

UnitedHealth Group’s Optum, CVS Health’s Signify and Oak Street, Humana’s CenterWell, and Elevance’s Carelon have acquired large primary-care groups. Valuation is anchored to attributed Medicare Advantage lives, not traditional EBITDA multiples. UnitedHealth 10-K filings disclose the Optum Health segment.

4. Independent physician-owned MSOs and roll-ups

Physician-founded MSOs are re-emerging in 2025-2026 as some doctors prefer to sell to peer-owned platforms rather than PE. Multiples typically run 1x to 2x below PE-backed platforms but include better retained clinical autonomy.

5. Strategic buyers (non-PE, non-hospital)

Diagnostic labs, medical device makers, and adjacent-service providers buy practices for distribution or vertical-integration reasons. These are rare and idiosyncratic.

For a broader framing of these buyer categories, see Strategic Buyer vs Financial Buyer and Family Office vs PE Buyer.

Income approach: DCF cross-check

The income approach discounts projected free cash flow using a specialty-specific weighted average cost of capital (WACC). For medical practices, WACC in 2026 typically runs 10 to 14 percent, reflecting a risk-free rate around 4.3 percent per Treasury yield curves, an equity risk premium of 5.0 to 5.5 percent per Damodaran, and a specialty beta of 0.8 to 1.1.

Buyers rarely rely on DCF for a small practice because forecasting five years of clinician retention, payer contracts, and reimbursement changes carries a high error bar. DCF is used as a sanity check on the market-multiple output. When the two approaches diverge by more than 20 percent, the assumptions get revisited.

Asset approach: the floor

The asset approach sums the fair market value of tangible assets (equipment, leasehold improvements, receivables at net realizable value, inventory) minus liabilities. For an operating practice with an active patient base, this typically undervalues the business by 60 to 90 percent versus the market-multiple output. Its practical uses are:

• Liquidation floor if the practice cannot be sold as a going concern.
• Purchase price allocation under IRS Form 8594 after the total transaction value is set.
• Insurance replacement valuation.

Deal structure and its impact on valuation

Two practices with identical EBITDA can trade at very different implied multiples depending on structure. The critical structural terms:

Rollover equity

PE-backed MSO deals typically require the seller to roll 20 to 40 percent of proceeds into equity of the acquiring platform. Rollover creates a “second bite” at a future exit, but it is illiquid and correlated with the buyer’s operating risk.

Earnouts

Earnouts of 10 to 20 percent of headline price are common in healthcare deals, tied to same-store EBITDA growth over 12 to 36 months. Federal-program-referral-based earnouts are prohibited.

Working capital peg

The working capital peg sets the target net working capital delivered at close. In a receivables-heavy practice, a poorly negotiated peg can transfer 5 to 15 percent of enterprise value from seller to buyer.

Retention compensation

Post-close physician compensation must be at FMV. Above-FMV compensation is treated as a purchase-price kicker; below-FMV compensation is treated as a giveback.

For structural detail, see Business Sale Letter of Intent Template and Due Diligence Checklist.

Rules of thumb (and why they mislead)

“Rule of thumb” valuations circulate widely in medical practice sales. The most common ones are wrong often enough that experienced buyers ignore them:

• “60 to 70 percent of one year’s collections.” This is a legacy rule for small primary-care solo practices. It ignores EBITDA quality, payer mix, and specialty, and it produces prices meaningfully below fair value for scaled specialty practices.
• “1x revenue.” Roughly correlates with a mid-single-digit EBITDA multiple only if the practice runs a 15 to 20 percent EBITDA margin, which most do not.
• “Book value plus goodwill of $50K per physician.” Obsolete outside of internal partner buy-ins.

Rules of thumb are useful only for a rough gut check. For any transaction above $500K in headline value, run the market-multiple method with specialty benchmarks and cross-check with a DCF.

Where valuation fits in the sale process

Valuation is not a single event; it is a range refined at four points in a sale process:

1. Pre-launch valuation opinion. Set expectations for the seller and design the process.
2. Market check via CIM and IOI round. Buyer indications of interest set the observed high end and low end.
3. LOI valuation. Refined after management meetings and initial data-room review.
4. Post-QoE final valuation. Buyers re-price after Quality of Earnings; sellers with a pre-launch sell-side QoE lose less value at this step.

The broader mid-market process is walked through in Investment Banking Process for Selling a Company and How to Sell My Business: Mid-Market Playbook.

How CT Acquisitions supports medical practice valuations

CT Acquisitions is a lower-middle-market M&A advisory firm advising healthcare-services owners on sell-side and buy-side transactions from $1M to $50M in enterprise value. On the sell-side, CT builds the normalized EBITDA bridge, benchmarks against 100+ vetted institutional buyers, runs a competitive process, and negotiates PC/MSO structure. Owner-aligned fee terms mean the incentive is on delivering the higher end of the multiple range, not on transaction volume.

FAQ: how to value a medical practice

How do you calculate the value of a medical practice?

Calculate practice value by (1) normalizing EBITDA to remove owner compensation above FMV, non-recurring costs, and personal expenses, (2) applying a specialty-specific EBITDA multiple drawn from recent transaction comps, and (3) valuing real estate separately at a cap rate. Cross-check the market-multiple output with a discounted cash flow model using a WACC of 10 to 14 percent. For CPOM states, split the professional corporation and the MSO and value each separately.

What multiple do medical practices sell for in 2026?

Medical practices sell for 4x to 15x normalized EBITDA in 2026, depending on specialty, scale, payer mix, and buyer type. Primary care sits at the low end (4x to 7x), veterinary and GI at the high end (10x to 15x), with dermatology, cardiology, and ophthalmology in between. Sub-$1M EBITDA practices trade below the low end; $5M+ EBITDA platforms often clear the top of the range.

How much is a doctor’s practice worth?

A doctor’s practice is worth normalized EBITDA multiplied by the specialty multiple, plus separately valued real estate, minus long-term debt. A dermatology practice with $2M of normalized EBITDA in a permissive-CPOM state may be worth $16M to $24M in enterprise value on the operating business, plus real estate. A solo primary-care practice with $400K of EBITDA may be worth $1.2M to $2.8M. The multiple is the largest driver of the number.

What is the rule of thumb for valuing a medical practice?

Legacy rules of thumb (60 to 70 percent of collections, 1x revenue, book value plus $50K per physician) survive but mislead in most modern transactions. Buyers with institutional capital price on normalized EBITDA and specialty multiples, not gross collections. Rules of thumb may work for a very rough estimate of a solo primary-care sale to another physician; they underprice most scaled specialty practices by 30 to 60 percent.

Does the buyer pay more for a practice in a CPOM state or a permissive state?

All else equal, buyers pay 0.5x to 1.5x lower multiples in strict corporate-practice-of-medicine states versus permissive states. The discount reflects the structural complexity of separating the PC and MSO, regulatory scrutiny (FTC, HHS OIG, state medical boards), and enforcement risk on the management fee structure. Practice quality and specialty still drive the base multiple; CPOM is a modifier.

How is real estate valued when selling a medical practice?

Practice-owned real estate is valued separately from the operating business at a capitalization rate. Medical office building cap rates ran 6.5 to 8.5 percent in 2025 per CBRE. Buyers typically prefer a 12 to 18 year triple-net leaseback rather than acquiring the real estate. If the seller retains the real estate, the leaseback creates a long-duration income stream separate from the sale proceeds.

What is personal goodwill and does it matter in a medical practice sale?

Personal goodwill is the intangible value tied to the individual physician (name, reputation, patient loyalty). Allocating value to personal goodwill can save 10 to 20 points of effective tax rate for a C-corp seller by avoiding double taxation, per Martin Ice Cream Co. v. Commissioner and H&M Inc. v. Commissioner. Buyers routinely resist because it reduces their amortizable basis and their non-compete use.

Are physician non-competes still enforceable after the FTC rule?

Yes, in most states, as of July 2026. The FTC’s April 2024 non-compete rule was vacated nationwide by Ryan LLC v. FTC in August 2024 and the ruling was affirmed on appeal. Physician non-competes are governed by state law and vary widely: California, Minnesota, North Dakota, and Oklahoma broadly prohibit them; most other states enforce reasonable time and geography restrictions. Enforceability directly affects the multiple a buyer will pay.